Trial Profile
A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc [epirubicin + cyclophosphamide + docetaxel] With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GeparQuattro
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 05 Jul 2017 Results assessing prognostic value of circulating tumor cells detected before and after neoadjuvant therapy, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 13 May 2016 Results of pooled sub-group analysis assessing PIK3CA mutations from GeparQuattro, GeparQuinto, GeparSixto, NeoALTTO and CHERLOB trials (n=967) published in the Annals of Oncology